Alto Neuroscience (ANRO) Competitors

Sagimet Biosciences (NASDAQ:SGMT) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Which has stronger earnings and valuation, SGMT or ANRO?

Sagimet Biosciences has higher revenue and earnings than Alto Neuroscience. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	157.03	-$45.57M	-$1.76	-5.82
Alto Neuroscience	N/A	N/A	-$61.43M	-$2.34	-1.32

Does the media refer more to SGMT or ANRO?

In the previous week, Alto Neuroscience had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 22 mentions for Alto Neuroscience and 14 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.58 beat Alto Neuroscience's score of 0.22 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	5 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, SGMT or ANRO?

Sagimet Biosciences has a beta of 3.35, suggesting that its stock price is 235% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.

Do analysts recommend SGMT or ANRO?

Sagimet Biosciences currently has a consensus price target of $26.83, indicating a potential upside of 162.04%. Alto Neuroscience has a consensus price target of $8.50, indicating a potential upside of 175.97%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alto Neuroscience	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Do institutionals and insiders have more ownership in SGMT or ANRO?

87.9% of Sagimet Biosciences shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 11.1% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is SGMT or ANRO more profitable?

Sagimet Biosciences' return on equity of -35.21% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-35.21%	-34.09%
Alto Neuroscience	N/A	-39.35%	-33.86%

Summary

Sagimet Biosciences beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.